[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351430-105":59,"doc-detail-351430-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","leveraging-quantitative-proteomics-and-extracellular-vesicle-data-to-uncover-druggable-receptor-kinases-across-cancers","Leveraging Quantitative Proteomics and Extracellular Vesicle Data to Uncover Druggable Receptor Kinases Across Cancers","","Extracellular vesicles (EVs) shape cancer progression and metastasis, and expanding clinical proteomics enables discovery of biomarkers and therapeutic targets in cancer-specific EVs. An integrated analysis combines an EV protein catalog with data from blood plasma and cancer cell surfaces to identify EV-associated proteins. Quantitative proteomics across 12 cancer types (n=2,272) yielded 3,250 shared EV-study proteins. Focusing on receptor kinases, PTK7 showed high expression or survival association in seven independent cohorts. Drug repurposing network analysis and RNAi screening support PTK7 as a candidate target lacking FDA-approved cancer drugs, providing a prioritization framework for downstream EV-driven therapy research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/leveraging-quantitative-proteomics-and-extracellular-vesicle-data-to-uncover-druggable-receptor-kinases-across-cancers/351430/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/leveraging-quantitative-proteomics-and-extracellular-vesicle-data-to-uncover-druggable-receptor-kinases-across-cancers/351430.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the integrated analysis in this study?","Question",{"text":112,"@type":113},"To identify EV-associated proteins, especially receptor kinases, and evaluate their potential as therapeutic targets across cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were receptor kinases prioritized in the analysis?",{"text":117,"@type":113},"The study focused on receptor kinases showing significant high expression in cancer types and also detected in EVs, then assessed expression and survival associations across independent cohorts.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports PTK7 as a potential therapeutic target?",{"text":121,"@type":113},"PTK7 emerged as a significant receptor kinase with high expression or survival association in seven independent cancer cohorts, and druggability analyses (drug repurposing network and RNAi screening) suggest therapeutic potential without FDA-approved cancer drugs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351430,1790431332,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Journal of Extracellular Vesicles  \nRESEARCH ARTICLE   \nLeveraging Quantitative Proteomics and Extracellular Vesicle Data to Uncover Druggable Receptor Kinases Across Cancers  \nJina Kim1, 2   Su Yeon Yeon3  Kyerim Choi4  Hojung Kim3  Hyoyoung Kim1  Daehee Hwang3  Sungyong You1, 2, 5  \n1 Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA  2 Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA  3 Department of Pathology, University of Illinois Chicago, Chicago, Illinois, USA  4 School of Biological Sciences, Seoul National University, Seoul, Republic of Korea  5 Samuel-Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA  \nCorrespondence: Sungyong You ([sungyong.you@cshs.org](sungyong.you@cshs.org))  \nReceived: 20 August 2025  Revised: 10 February 2026  Accepted: 20 March 2026  \nKeywords: extracellular vesicles | therapeutic targets | pan-cancer | proteomics | receptor kinases  \nABSTRACT  \nExtracellular vesicles (EVs) play an important role in cancer progression and metastasis. The increasing clinical proteomics data provides an opportunity to uncover new biomarkers and therapeutic targets in cancer specific EVs. Here, we present an integrated data analysis approach that leverages a comprehensive protein catalog from EVs, blood plasma, and the cancer cell surface to identify EV-associated proteins and evaluate their potential as therapeutic targets in cancer cells. Quantitative proteomics data from 12 cancer types (n = 2,272) identified 3,250 proteins that are commonly found in EV studies and EV quantity data. Receptor kinases (RKs) are crucial in cancer signalling pathways and have been widely studied targets. Our analysis focused on identifying RKs with significant high expression in cancer types that were also detected in EVs. Notably, PTK7 emerged as a significant target with high expression or survival association in seven independent cancer cohorts. We then explored the druggability of the RKs. Our analysis of drug repurposing network and RNAi screening suggested PTK7 as a potential therapeutic target with no FDA approved drugs in cancer. Overall, this integrative analysis proposes a framework to prioritize EV-associated candidates for downstream therapeutic investigation in cancer.  \n1  Introduction  \nCancer research has increasingly highlighted the importance of integrating diverse data sources to better understand tumour biology and identify therapeutic targets. The Clinical Proteomic Tumour Analysis Consortium (CPTAC) has been pivotal in providing proteogenomic datasets through the Proteomic Data Commons (PDC) (Thangudu et al. 2020), the National Cancer Institute’s (NCI) largest public repository of proteogenomic comprehensive tumour datasets. Recent trends in proteomic research have also driven towards comprehensive analysis through inte-  \ngration and comparison of various data beyond transcriptomics (Li et al. 2023) . Recent proteomic pan-cancer studies revealed changes in protein acetylation and phosphorylation patterns (Geffen et al. 2023) and focused on comprehensive analysis in understanding functional status of oncogenic drivers (Li et al. 2023) .  \nExtracellular vesicles (EVs) have emerged as critical players in cancer biology, serving as nanosized carriers of molecules that facilitate intercellular communication. Due to their ability to encapsulate molecules, their significance has drawn attention  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.  \nJournal of Extracellular Vesicles, 2026; 15:e70275 1 of 16  \n[https://doi.org/10.1002/jev2.70275](https://doi.org/10.1002/jev2.70275)  \n","cbCairFLCirDY0l8","https://ap.wps.com/l/cbCairFLCirDY0l8","pdf",5076756,16,"English","# Introduction\n## Data integration and rationale\n## EVs as carriers of biomarkers and targets\n## Receptor kinases in EV-mediated signaling\n## Study objective and druggability focus","[{\"question\":\"What is the main goal of the integrated analysis in this study?\",\"answer\":\"To identify EV-associated proteins, especially receptor kinases, and evaluate their potential as therapeutic targets across cancers.\"},{\"question\":\"How were receptor kinases prioritized in the analysis?\",\"answer\":\"The study focused on receptor kinases showing significant high expression in cancer types and also detected in EVs, then assessed expression and survival associations across independent cohorts.\"},{\"question\":\"What evidence supports PTK7 as a potential therapeutic target?\",\"answer\":\"PTK7 emerged as a significant receptor kinase with high expression or survival association in seven independent cancer cohorts, and druggability analyses (drug repurposing network and RNAi screening) suggest therapeutic potential without FDA-approved cancer drugs.\"}]","Leveraging Quantitative Proteomics and Extracellular Vesicle Data to Uncover Druggable Receptor Kinases Across Cancers | PDF",1790094134,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4282f60fcc6bb22bfe2d5cb33058ae7f.webp",983,1283,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3330ce68a1215bb0fd090a23129f57b3.webp",982,1281,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7bf75945c89e2b57a26c7dc1a8f272c.webp",981,1280,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdabed20ceda53f21660c5d326a8ff9d.webp",980,1279]